By submitting this form you agree to be contacted by KirkendallDwyer.com affiliates and/or attorneys regarding your claim. You consent to KirkendallDwyer.com contacting you through the use of text message, phone call, and electronic mail message even if your number is a wireless number or if I am presently listed on a Do Not Call list. My consent does not require purchase.
Xarelto, an alternative to warfarin, the traditional treatment for atrial fibrillation, has suffered another rejection by the FDA. This is the second time that Johnson & Johnson has tried to get Xarelto approved to treat acute coronary syndrome, and the second time the FDA has refused to do so.